Business Context and Reporting Period
This Form 8-K Current Report was filed by Visteon Corporation on November 14, 2008. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the Company's stock price performance relative to exchange listing requirements.
Material Changes
The primary material event reported is the notification from the NYSE that Visteon Corporation's common stock fell below the minimum average closing price of $1.00 over a consecutive 30 trading-day period, as required by Rule 802.01C of the NYSE Listed Company Manual.
Outlook, Management Commentary, and Risks
- Management Action: The Company intends to notify the NYSE of its plan to cure the deficiency.
- Compliance Timeline: Visteon has six months from the receipt of the notice to bring its share price and average share price back above $1.00.
- Consequences of Non-Compliance: Failure to regain compliance within the six-month period will subject the Company to suspension and delisting procedures.
- Current Status: The Company's common stock will remain listed on the NYSE during the cure period, provided it complies with other continued listing requirements.
Investor Verification Checklist
- Verify the current trading price and 30-day average closing price of Visteon common stock.
- Monitor the Company's progress toward the $1.00 price threshold within the six-month cure period.
- Review subsequent filings for any updates on the cure plan or potential delisting proceedings.
- Check for any additional financial disclosures in the referenced press release (Exhibit 99.1) not included in this summary.